A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008335/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and
efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice
in patients who have locally advanced and/or metastatic breast cancer with germline BRCA
mutations.
提供机构：
Vivli
创建时间：
2022-08-11
